Accuray Incorporated

Welcome

BiotechProfiles™ is the premier resource for jobs, company information, professional networking and productivity tools in the Madison, Wisconsin biotechnology and medical device industry. Recognized as one of the premier emerging biotechnology clusters in the U.S., this robust industry sector comprises nearly 10,000 employees in approximately 150 companies. BiotechProfiles also maintains a unique directory of the largest 250 pharmaceutical companies worldwide, including business development contacts whenever available. This tool is indispensable for executives pursuing strategic alliances and technology licenses.
Designed as a suite of easy to use, searchable databases that are continually updated, BiotechProfiles serves the needs of biotech business development and operational executives in early stage companies, as well as the general public. With these tools you can quickly bypass the data collection and screening stage and immediately focus on solving your strategic partnering or operational needs. We've assembled your background data for you!
  Next »

BiotechProfiles is also the premier site for data on Biotechnology Companies in Madison Wisconsin, Biotechnology Jobs in Madison Wisconsin

Biotechnology Companies in Madison Wisconsin; Biotechnology Jobs in Madison Wisconsin
  « Previous | Next »

Biotechnology Business Development, Partnering and Strategic Alliances

Biotechnology Business Development, Partnering and Strategic Alliances
  « Previous | Next »

Madison Biotechnology Companies; Madison Biotechnology Jobs

Madison Biotechnology Companies; Madison Biotechnology Jobs
  « Previous | Next »

List or rank of Largest Pharmaceutical Companies Worldwide

List of rank of Largest Pharmaceutical Companies Worldwide
  « Previous

Advertisement

Company Profile

Accuray Inc. (formerly known as TomoTherapy Incorporated) has developed, manufactures and sells the Hi·Art® treatment system, one of the most advanced and versatile radiation therapy systems commercially available for the treatment of a wide variety of cancers. The Hi·Art system precisely delivers radiation with sub-millimeter accuracy to kill cancer cells while reducing radiation exposure to surrounding healthy tissue. The Hi·Art system contains a linear accelerator, which is a device that generates external beam radiation that is used both to capture high-quality, quantitative images and to deliver therapeutic radiation in a helical, or spiral, delivery pattern from 360 degrees around the patient. Headquartered in California, the company maintains research and manufacturing operations in Madison.
Business Sectors
Pharmaceuticals   Human Diagnostics  
Med or Lab Devices Lab Reagents or Services  
Drug Manufacturing   Food & Agribusiness  
CRO   Bioinformatics or Software  
    Other  
Company History
Rock Mackie and Paul Reckwardt found TomoTherapy in 1997. The company receives 510(k) approval to market its Hi-Art treatment system in 2002. The company successfully raised $42 million of equity financing prior to going public. TomoTherapy raised $223M in its IPO in May 2007, with a market cap of >$800 million. In March 2011, Accuray announced that it would acquire TomoTherapy for $277 million, maintaining core R&D and manufacturing in Madison. The transaction closed in June 2011.

LEADERSHIP ROLL: Rock Mackie 1997-2005; Fred Robertson 2005-2011
Accuray Incorporated
Address 1240 Deming Way
[Map] Madison
WI
53717-1954
Phone 608-824-2800
Fax 608-824-2990
Website Link
Head Robert Zahn
Company Statistics
Global Headcount 1000
Local Headcount 290
Year Founded 1997
Ownership Subsidiary
Stock Exchange

Parent Company
Divisional Level
Senior Level
Global Headcount
Website
Stock Exchange
Reference Documents
News/Profiles
2016 - Accuray Growth Profiled [View]
2010 - TomoTherapy Is Radiating Optimism [View]
2007 - TomoTherapy Hits Ground Running [View]
2007 - Tomotherapy IPO Raises $223 Million [View]
2005 - Zooming in on Cancer [View]
Reports
TomoTherapy 2009 SEC Form 10-K [View]
Selected Press Releases
2011 - Accuray to Acquire TomoTherapy for $277M [View]